748 completed, 247 terminated, 182 recruiting, 144 active not recruiting. 1592 Phase 2, 450 Phase 1, 31 Phase 3.
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-10-28 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Zealand University Hospital | 150 | 2027-03-01 | 2026-09-25 |
| MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | University of Arkansas | 50 | 2027-03-01 | 2026-09-02 |
| Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 70 | 2027-01-01 | 2026-09-30 |
| Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab, VRD - Multiple Myeloma | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 15 | 2027-01-01 | 2026-10-02 |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma CAR-T cells - Multiple Myeloma, Plasmacytoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-08-27 |
| Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma CAR T cells - Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-10-30 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma CAR-T cells, BCMA bispecific - Myeloma Multiple | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 44 | 2026-12-01 | 2026-10-09 |
| BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma BAFF CAR-T - Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory | Phase 2 | Not yet recruiting | Luminary Therapeutics | 90 | 2026-12-01 | 2026-08-18 |
| QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease QLS4131 - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 55 | 2026-12-01 | 2026-10-29 |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma Mirdametinib, Sirolimus - Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 54 | 2026-11-04 | 2026-10-30 |
| Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias Avatrombopag - Thrombocytopenia | Phase 2 | Not yet recruiting | University of Virginia | 26 | 2026-11-01 | 2026-10-26 |
| A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma Belantamab mafodotin - Relapsed/Refractory Multiple Myeloma | Phase 2 | Withdrawn | Cristiana Costa Chase, DO | 2026-11-01 | 2026-09-28 | |
| Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Dexamethasone, Mezigdomide, Elranatamab - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Not yet recruiting | PETHEMA Foundation | 60 | 2026-11-01 | 2026-10-28 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Recruiting | Hoffmann-La Roche | 45 | 2026-10-30 | 2026-10-15 |
| CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma CM336 (BCMA/CD3 bispecific antibody), Daratumumab, Lenalidomide - Multiple Myeloma | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-10-15 | 2026-10-26 |
Showing 20 of 1592. Sign in to see all of them.
Neoplasms, Plasma Cell (275) · Lymphoma (194) · Recurrence (193) · Lymphoma, Non-Hodgkin (192) · Hodgkin Disease (172) · Leukemia, Lymphocytic, Chronic, B-Cell (156) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (146) · Leukemia, Myeloid, Acute (143) · Myelodysplastic Syndromes (142) · Leukemia (139) · Lymphoma, Mantle-Cell (111) · Lymphoma, Follicular (110) · Lymphoma, B-Cell, Marginal Zone (102) · Lymphoma, Large B-Cell, Diffuse (102)
Hemic and Lymphatic Diseases (1592) · Immune System Diseases (1587) · Immunoproliferative Disorders (1587) · Neoplasms by Histologic Type (1584) · Vascular Diseases (1581) · Cardiovascular Diseases (1580) · Hemorrhagic Disorders (1580) · Hemostatic Disorders (1580) · Lymphoproliferative Disorders (1575) · Blood Protein Disorders (1571) · Hematologic Diseases (1569) · Paraproteinemias (1567) · Neoplasms (1536) · Neoplasms, Plasma Cell (1317) · Pathological Conditions, Signs and Symptoms (354)
Dexamethasone (487) · Lenalidomide (256) · Bortezomib (252) · Cyclophosphamide (206) · Melphalan (169) · Calcium Dobesilate (155) · daratumumab (130) · carfilzomib (110) · pomalidomide (110) · Peripheral Blood Stem Cell Transplantation (83) · fludarabine phosphate (82) · Filgrastim (69) · Thalidomide (65) · Mycophenolic Acid (63) · Busulfan (60)
National Cancer Institute (NCI) (88) · Mayo Clinic (53) · Fred Hutchinson Cancer Center (47) · M.D. Anderson Cancer Center (42) · Memorial Sloan Kettering Cancer Center (42) · University of Arkansas (31) · Institute of Hematology & Blood Diseases Hospital, China (25) · Celgene (23) · H. Lee Moffitt Cancer Center and Research Institute (21) · Janssen Research & Development, LLC (21) · Masonic Cancer Center, University of Minnesota (19) · GlaxoSmithKline (18) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (17) · Amgen (16) · City of Hope Medical Center (15)
United States (1039) · China (128) · France (113) · Spain (112) · Germany (104) · Canada (100) · Italy (92) · United Kingdom (69) · Australia (64) · Greece (59) · South Korea (54) · Japan (41) · Netherlands (40) · Denmark (38) · Belgium (35)
Brenda Sandmaier (9) · James R Berenson, MD (7) · Paul Richardson, MD (7) · Shaji Kumar (7)
PMID 32499241, PMID 33357481, PMID 35285981, PMID 35549810, PMID 31221778, PMID 34182226, PMID 37934000, PMID 40156952, PMID 19179301, PMID 20661232, PMID 21403127, PMID 22430088, PMID 25628469, PMID 25824111, PMID 26181891, PMID 26308596, PMID 26690712, PMID 27307294, PMID 29025767, PMID 29567784, PMID 30536810, PMID 30957581, PMID 31433920, PMID 31527168, PMID 32107329, PMID 32463741, PMID 32470437, PMID 34465265, PMID 34826409, PMID 35132679, PMID 37022569, PMID 37270762, PMID 38649340, PMID 38826786, PMID 40000533, PMID 40471585, PMID 40501401, PMID 40826257, PMID 42287565, PMID 10084252, PMID 10414913, PMID 10414914, PMID 10459351, PMID 10482933, PMID 10564685, PMID 10918404, PMID 12000194, PMID 12473574, PMID 14508361, PMID 14767498
U10CA180820 (37), P30CA015083 (31), 2023 (29), P30CA015704 (21), U24CA196172 (20), 2017 (18), 2019 (12), 2025 (12), 2008 (9), 2018 (9), P30CA006973 (9), U10CA032102 (9), 2005 (8), P30CA033572 (8), 2014 (7)